Valbiotis' Lipridrive Demonstrates Efficacy in Phase II/III Trial for Hypercholesterolemia
• Valbiotis' Lipridrive met its primary endpoint in a Phase II/III trial, significantly reducing LDL cholesterol in patients with mild to moderate hypercholesterolemia.
• The international, multicenter, randomized, placebo-controlled study involved 180 subjects receiving a 5g daily dose of Lipridrive over three months.
• Lipidrive showed excellent safety and tolerability, with compliance exceeding 98%, reinforcing its potential as a well-received therapeutic option.
• Full results from the HEART II study will be presented at international congresses and published in peer-reviewed journals.
VALBIOTIS Announces Interim Financial Statements and Strategic Developments
VALBIOTIS has published its interim financial statements, highlighting significant progress in its product launches, clinical trials, and strategic reorganization. The company is focusing on marketing its dietary supplements, with plans for future launches and international expansion. Financial details reveal a solid cash position and strategic investments in sales and marketing.
VALBIOTIS SA: Phase II/III REVERSE-IT Study to be Presented at 2023 EASD Congress
The Phase II/III REVERSE-IT study, conducted by Valbiotis in partnership with Nestlé Health Science, has been selected for an oral presentation at the 2023 European Association for the Study of Diabetes (EASD) congress. The study focuses on the efficacy of TOTUM•63, a non-drug active substance, in addressing early glycemic disorders.
Valbiotis Announces Success of REVERSE-IT Clinical Study on TOTUM-63
Valbiotis SA has reported significant success in the REVERSE-IT Phase II/III clinical study on TOTUM-63, showing its efficacy in reducing fasting blood glucose in prediabetic and untreated type 2 diabetic patients. This achievement has triggered a CHF 4 million payment from Nestlé Health Science as part of their global strategic partnership.
Valbiotis Announces Major Success in Phase II HEART Clinical Study for TOTUM-070
Valbiotis has reported significant success in its Phase II HEART clinical study, demonstrating that TOTUM-070, a patented plant-based active substance, effectively reduces LDL cholesterol and triglycerides, key cardiovascular risk factors, in individuals with mild to moderate hypercholesterolemia. The study, involving 120 volunteers, showed promising results after just three months of supplementation, with plans for commercialization by the first half of 2024.
© Copyright 2025. All Rights Reserved by MedPath